Priming Immunity at the beginning of Life - Follow-up 12 months
Networks
-
Variables
-
Efficacy of Bifidobacterium longum subsp. infantis, Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (La-5) probiotics early in life of preterm infants to prevent colonization with multidrug-resistant organisms or highly epidemic bacteria (MDRO+) and to shape the microbiome of preterm infants toward the eubiotic state of healthy full-term infants.
Associated study
- Germany
| Acronym | PRIMAL |
|---|---|
| Name | Priming Immunity at the beginning of Life |
| Study design | Clinical trial |
| Number of very preterm (VPT) and/or very low birthweight (VLBW) births included in cohort (live & still births) | 475 |
| Number of term-born control births included in cohort (live & still births) | 0 |
| Countries |
|
Population
PRIMAL
Inclusion of moderate preterm infants born at 28+0 to 32+6 weeks of gestational age
Data Collection Event
FU 12 months
12 month Follow-up data collection via structured telephone interviews with parents and a physician and cognitive examinations (1-year onsite subgroup)